跳至主要内容
临床试验/NCT00972777
NCT00972777已完成2 期

A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis.

Bausch & Lomb Incorporated1 个研究点 分布在 1 个国家目标入组 474 人开始时间: 2009年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
474
试验地点
1
主要终点
Clinical Resolution

研究概览

简要总结

This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
1 Year 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who are at least one year of age.
  • Subjects who have a clinical diagnosis of acute bacterial conjunctivitis.
  • Subjects who are willing to discontinue contact lens wear for the duration of the study.

排除标准

  • Subjects who have any uncontrolled systemic disease or debilitating disease.
  • Subjects with known sensitivity or contraindications to besifloxacin, fluoroquinolones or any ingredients in study drugs.
  • Subjects who are expected to require treatment with any disallowed medications.

研究组 & 干预措施

Besifloxacin

Experimental

0.6% ophthalmic suspension

干预措施: Besifloxacin (Drug)

Vehicle

Placebo Comparator

干预措施: Vehicle (Placebo) (Drug)

结局指标

主要结局

Clinical Resolution

时间窗: Visit 2

The absence of both conjunctival discharge and bulbar conjunctival injection.

Microbial Eradication

时间窗: Visit 2

The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline.

次要结局

  • Clinical Resolution(Visit 3)
  • Microbial Eradication(Visit 3)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验